Viking Therapeutics Inc

VKTXNASDAQ · USD
33.03USD0.00 (-7.12%)
127

Viking Therapeutics Inc (VKTX) Option Chain

As of September 28, 2026, Viking Therapeutics Inc is trading at $33.03, a -7.12% change from the previous close. The nearest expiration is Oct 2, 2026. Implied volatility is 70.5%. IV Rank is 20%.

Read more

Tracking the VKTX option chain helps you see every strike and expiry on Viking Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Viking Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of VKTX options activity at a glance. Use our scanner to monitor the VKTX option chain in real time and filter for the VKTX options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For VKTX stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the VKTX option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where VKTX stock options are being actively traded and where they are not.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

The company was incorporated in 2012 and is headquartered in San Diego, California.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Viking Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen VKTX options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of VKTX stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile1.19% Subdued
  • Market cap (M$)3,853
  • 52 weeks high-23.45%
  • 52 weeks low31.91%
  • Analyst recommendationStrong Buy
    1.20
  • Target price$95.67
    189.65% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-10-28
  • P/E—
  • Future P/E—
  • EPS (ttm)-4.66
  • EPS growth next 5 years-3.63%

As of September 28, 2026

2026-10-02
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
15.4324812.851.032.415.3532.00-10.010.150.260.000.2115011684.57
19.431202.840.532.094.6532.50-8.610.180.300.000.242086380.57
23.92824283.320.032.354.3533.00-7.200.300.380.000.34518076.08
28.852822.650.001.393.9033.50-5.790.330.850.470.12768071.15
34.14419472.150.001.642.6634.00-4.390.540.700.97-0.3516819665.86

As of September 28, 2026

Scan the full option chain in one place

Browse the full VKTX option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial